couple of broker upgrades on DJ news feed
"DJ CSL Target Price Lifted 20% to A$300 a Share by Macquarie"
"Although competitors to Aussie pharma company CSL are working on new treatments for haemophilia, Macquarie still believes that CSL's key Idelvion therapy is "well placed over the medium term." The investment bank expects Idelvion to continue its revenue and market share growth as it becomes available in new geographies over the next 12 months. Macquarie is also bullish on CSL's plasma-collection center network, noting that it is a competitive advantage relative to peers and enables a constant supply of key plasma-derived products"
"DJ CSL Target Lifted 22% to A$305 a Share by Credit Suisse"
couple of broker upgrades on DJ news feed "DJ CSL Target Price...
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$275.80 |
Change
0.410(0.15%) |
Mkt cap ! $133.2B | |||
| Open | High | Low | Value | Volume |
| $276.00 | $277.50 | $274.44 | $131.0M | 472.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83 | $275.78 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $275.93 | 109 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$276.25 |
Change
0.410 ( 0.14 %) |
||||
| Open | High | Low | Volume | ||
| $276.01 | $277.50 | $274.48 | 149758 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| CSL (ASX) Chart |